Vifor Pharma acquires US$50m share in Akeb...Swiss Vifor Pharma has agreed to acquire shares of Cambridge-based distributor Adebia worth US$50m in order exclusivly distribute its hypoxia-inducible factor (HIF) stabiliser vadadustat to 40% of US … more ➔
NSCLC: AstraZenecas durvalumab meets PFS...AstraZenecas anti PD-L1 antibody durvalumab has met the co-primary endpoint in non-small cell lung cancer (NSCLC) in a Phase III trial vs placebo. OS data were not yet available. more ➔
Norgine to acquire Merus Dutch Norgine BV will take-over Merus Labs International Inc. Under the agreement, Norgine will acquire all outstanding shares for US$1.65 per share in cash. more ➔
Cheap Avastin as effective as Eylea in CRV...A study conducted by an NIH institute proves Roches Avastin is as effective as Regenerons Eylea, a drug that costs 30 times more than Roches antibody. The rub: Avastin is not approved for use in … more ➔
Roches anti-PD-L1 fails in bladder cance...Fiasco in Phase III: Roches conditionally approved PD-L1 checkpoint inhibitor did not meet the endpoint of overall survival vs chemotherapy in a confirmatory study with pre-treated patients with metastatic … more ➔
Dermtreat bags €16.2m financingMucosal inflammation specialist Dermtreat ApS (Copenhagen) has secured a Series A financing worth €16.2m (US$17.7m). more ➔
GMO acreage growingGMO world market adoption is further growing. GMO cultivation area in 2016 increased to 185.1 million hectares versus 2015 (179.7m hectares), 3% up globally, and from 116,870 in 2015 to 136,363 hectares, … more ➔
Another great year for Swiss biotech With an impressive 11.7% growth in sales compared with 2015, the Swiss biotech sector has grown more strongly in 2016 than the years before. However, after three years of growth, Swiss biotech companies … more ➔
German biotech on the riseThe Biotechnology in Germany is a growth engine. According to a new report, all key figures such as employees, turnover and R&D expenditure were at an all-time high in 2016. more ➔
€37.5 million for Vivet TherapeuticsThe french biotechnology company Vivet Therapeutics has raised €37.5 million in a Series A financing round. Amongst others, Novartis Venture Fund and Roche Venture Fund were involved. more ➔
